Erratum: Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial dataset [Ann Oncol (2014) 25, 2378-2385] DOI: 10.1093/annonc/mdu464;Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial dataset

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2378-2385

  Blons, H ^a,b,c   Emile, J F ^d,e   Le Malicot, K ^f   Julie C ^d   Zaanan, A ^c   Tabernero, J ^g   Mini, E ^h   Folprecht, G ⁱ   Van Laethem, J L ^j   Thaler, J ^k   Bridgewater, J ^l   Norgard Petersen L ^m   Van Cutsem, E ⁿ   Lepage, C ^o   Zawadi, M A ^p   Salazar, R ^q   Laurent Puig, P ^a,b,c   Taieb, Julien ^b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d APHP Ambroise Paré Hospital   (France)

^e Paris Ouest University   (France)

^f Fédération Francophone de Cancérologie Digestive ^*  (France)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j ERASME HOSPITAL   (Belgium)

^k Klinikum Wels Grieskirchen GmbH   (Austria)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m Rigshospitalet   (Denmark)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o Chu   (France)

^p Les Oudairies District Hospital   (France)

^q CATALAN INSTITUTE OF ONCOLOGY   (Spain)

more..

Author keywords

Cetuximab; Colorectal cancer; Distal colon; KRAS mutation; Prognosis; Proximal colon

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CODON; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TUMOR LOCALIZATION; WILD TYPE; CLINICAL TRIAL; COLONIC NEOPLASMS; GENETICS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PHASE 3 CLINICAL TRIAL; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; EXONS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84926296479     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv070     Document Type: Erratum

References (29)

1. Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ 2000; 321 (7264): 805-808.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
3. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27(19):3109-3116.
4. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17): 1757-1765.
5. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectaltumor development. N Engl J Med 1988; 319(9): 525-532.
6. Forbes SA, Bindal N, Bamford S et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39 (Database issue): D945-D950.
7. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22(7): 1535-1546.
8. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3): 374-379.
9. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360(14): 1408-1417.
10. Gavin PG, Colangelo LH, Fumagalli D et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18(23): 6531-6541.
11. Imamura Y, Morikawa T, Liao X et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18(17): 4753-4763.
12. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28(3): 466-474.
13. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85(5): 692-696.
14. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 1998; 90(9): 675-684.
15. Morikawa T, Kuchiba A, Qian ZR et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 2012; 19(6): 1944-1953.
16. Taieb J, Tabernero J, Mini E et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15(8): 862-873.
17. Blons H, Rouleau E, Charrier N et al. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. PLoS One 2013; 8(7): e68945.
18. Farina-Sarasqueta A, van Lijnschoten G, Moerland E et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21(12): 2396-2402.
19. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 2011; 12(2): 163-171.
20. Hutchins G, Southward K, Handley K et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29(10): 1261-1270.
21. Yoon H, Tougeron D, Mahoney M et al. Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: results from NCCTG N0147 (Alliance). Eur J Cancer 2013; 49: S484.
22. Yoon HH, Tougeron D, Shi Q et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014; 20(11): 3033-3043.
23. Benedix F, Meyer F, Kube R et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract 2012; 208(10): 592-597.
24. Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer-a systematic review. Dan Med J 2012; 59(6): A4444.
25. Weiss JM, Pfau PR, O'Connor ES et al. Mortality by stage for right-versus leftsided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data. J Clin Oncol 2011; 29(33): 4401-4409.
26. Oliveira C, Westra JL, Arango D et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13(19): 2303-2311.
27. Phipps AI, Buchanan DD, Makar KW et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012; 21(10): 1792-1798.
28. Phipps AI, Buchanan DD, Makar KW et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108(8): 1757-1764.
29. Janakiraman M, Vakiani E, Zeng Z et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70(14): 5901-5911.